Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis
Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis
About this item
Full title
Author / Creator
Publisher
United States: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
United States: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
In patients with prurigo nodularis, a severely pruritic skin disorder, the subcutaneously administered interleukin-31 receptor antibody nemolizumab was tested in a 12-week, phase 2 trial. The intensity of itching and overall severity of the disorder were more greatly reduced with nemolizumab than with placebo.
Alternative Titles
Full title
Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2359415992
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2359415992
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa1908316
